Loading
Eloxx Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Geffken Daniel E., was filed 01 Dec 2021.
Eloxx Pharmaceuticals, Inc.: what insiders have been doing
Eloxx Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 4 filings came from 2 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 4 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 3 purchases and no sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -6.0 m USD.
Insider buying of Eloxx Pharmaceuticals, Inc. has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 7 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -93.6%Entry US$28.25 · Close at T+365 US$1.82
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.70
Analyst consensus
4 analysts1.00/5
US$32.00Target US$38.25(+201%)US$43.00
Income statement
EBITDA-US$4.9M
Net income-US$6M0.0% margin
Valuation
PER (trailing)3.6x
P/Book1.1x
Beta-171332.88
Balance sheet & cash
Market capUS$51.3M
Total debtUS$1M
Free Cash Flow-US$6.3M
Debt / Equity25%
Profitability & ownership
% insiders19.1%
% institutions73.8%
Last declaration on 17 June 2026
Declarations23 total
238,422 sharescommon stock, $0.01 par value per shareSEC:0000919574-26-004021:0
361,578 sharescommon stock, $0.01 par value per shareSEC:0000919574-26-004021:1
113,636 shares0Common Stock, $0.01 par value per shareSEC:0000919574-26-003845:0
1,250,000 shares0Common StockSEC:0001104659-26-068440:0
3,750 shares0Common StockSEC:0001104659-25-006783:0
30,000 shares0Common StockSEC:0001104659-25-006784:0
3,750 shares0Common StockSEC:0001104659-25-006781:0
3,750 shares0Common StockSEC:0001104659-25-006782:0
12,000 shares0Common StockSEC:0001104659-24-109525:0
12,000 shares0Common StockSEC:0001104659-24-109524:0
165,000 shares0Common StockSEC:0001104659-24-109519:0
12,000 shares0Common StockSEC:0001104659-24-109523:0
219,326 shares0Common StockSEC:0001415889-21-005692:0
279,158 shares0Common StockSEC:0001415889-21-005693:0
37,695 shares0Common StockSEC:0001415889-21-005694:0
50,000 shares@ US$0.72100.0% of flowCommon StockSEC:0001415889-21-005600:0
Canonical exit: 27 Feb 2022 (T+90)
1,563 shares0Common StockSEC:0001415889-21-003750:0
6,250 shares0Common StockSEC:0001415889-21-002682:0
1,280,624 shares@ US$1.35100.0% of flowCommon StockSEC:0001104659-21-067333:0
Canonical exit: 11 Aug 2021 (T+90)
1,280,624 shares@ US$1.35100.0% of flowCommon StockSEC:0001104659-21-067335:0
Canonical exit: 11 Aug 2021 (T+90)
84,776 shares@ US$1.35100.0% of flowCommon StockSEC:0001104659-21-067516:0
Canonical exit: 11 Aug 2021 (T+90)
▲
Same trade as the filing by Ran Nussbaum, counted once · View ↗
1,280,624 shares@ US$1.35100.0% of flowCommon StockSEC:0001104659-21-067336:0
Canonical exit: 11 Aug 2021 (T+90)
1,562 shares0Common StockSEC:0001415889-21-002227:0
23 of 23 declarations
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States. The company focuses on developing next-generation therapies for rare and ultra-rare genetic diseases, using small-molecule approaches designed to promote readthrough of premature stop codons (“nonsense” mutations) and restore production of full-length functional proteins. In practical terms, Eloxx operates in precision medicine and rare-disease biotech, where valuation is driven less by current revenue and more by clinical validation, intellectual property, and financing capacity.
Eloxx traces its roots to Eloxx Pharmaceuticals, Ltd., with scientific and corporate links to Israel, while its U.S. operating footprint is centered in Massachusetts. Public company information shows a headquarters/contact presence in Watertown, Massachusetts, and SEC filing materials list a mailing/business address in Arlington, Massachusetts. That geographic setup reflects a transatlantic structure: U.S.-based public-company administration and financing, combined with research and IP elements associated with Israel and external academic collaborators. The company’s leadership has been stable in recent years, with Sumit Aggarwal serving as President and Chief Executive Officer since April 2021. Its board also includes experienced biotech, venture capital, and healthcare executives.
Read moreShow less
The company’s core asset is ELX-02, its lead investigational product candidate. Eloxx positions ELX-02 as a small-molecule drug designed to restore production of full-length proteins in diseases caused by nonsense mutations. The company currently highlights Alport syndrome as a lead program, while also working on other rare-disease opportunities and IND-enabling studies in areas such as kidney and ocular genetic disorders. Eloxx also references platform technologies including TURBO-ZM™ and eukaryotic ribosomal selective glycosides (ERSGs), which are intended to underpin a broader pipeline beyond a single indication.
From a competitive standpoint, Eloxx remains an early-stage clinical biotech rather than a commercial pharmaceutical company. It competes in a crowded field that includes rare-disease drug developers, gene-therapy companies, and other platform-driven players pursuing mutation-correction or readthrough strategies. The company’s strategic challenge is to translate promising biology into reproducible human data and then secure the capital needed to advance development. Recent public activity has included ongoing SEC filings, including Form 4 insider transactions filed in May 2026, underscoring that the market is still tracking corporate and ownership changes closely. For investors in France, Belgium, and Switzerland, Eloxx should be viewed as a high-risk, high-upside Nasdaq biotech story with meaningful binary clinical catalysts and a long development runway.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
